Avax Technologies
| Use attributes for filter ! | |
| Stock price | AVXT |
|---|---|
| Disclaimer | |
| Headquarters | Philadelphia |
| Pennsylvania | |
| United States | |
| Founded | 1990 |
| Subsidiaries | Genopoietic S. A. |
| AVAX Australia Pty ltd | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 844704 |
About Avax Technologies
Avax Technologies, Inc is a Philadelphia based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007.
